University of Minnesota

Lies and the career research subject

Wednesday, February 1, 2017

Patients can also lie about their health to be accepted into a trial. Some even make their “living” going from one trial to another. The problem will continue, some observers say, until a national registry is put into place to catch these kinds of problems.

[Read More]

Study shows that almost half of pediatric trials are not finished or published

Tuesday, November 1, 2016

As Research Practitioner highlighted earlier this year, clinical research results have been disclosed late or not at all at least 95% of the time since reporting of results from human studies to the federal government’s database became mandatory in 2008.1  Most of these trials, however, use adult subjects. Researchers at Boston’s Children Hospital in Massachusetts decided to examine the reporting of pediatric study results and found that almost half of the studies had been discontinued or not published.

[Read More]

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

[Read More]

Upsher-Smith announces positive data for epilepsy drug USL261

Friday, May 2, 2014

Upsher-Smith Laboratories has announced positive phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy. Results demonstrated that USL261 at a single dose of up to 7.5mg was rapidly absorbed and exhibited a short half-life. Additionally, USL261 generally was well-tolerated in patients with epilepsy and demonstrated a rapid onset of pharmacodynamic effects with return to baseline function by four hours post dose.

[Read More]